Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

December 30, 2017

Study Completion Date

December 31, 2027

Conditions

Smoldering Plasma Cell Myeloma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER